Preclinical research finds that glioblastoma stem cells can be targeted by NK cells, but they are able to evade immune attack by releasing TFG-β. Deleting the TFG-β receptor in NK cells renders them resistant to this and restores their anti-tumor activity.
MD Anderson researchers have discovered a new role for the metabolic enzyme, MCAD, in glioblastoma. The enzyme prevents toxic fatty acid accumulation, in addition to its normal role in energy production, and targeting MCAD led to irreversible damage and cell death specifically in cancer cells.
Piperlongumine, a chemical compound found in the Indian Long Pepper plant, is known to kill cancerous cells in many tumor types. Now an international team including researchers from Penn has illuminated one way in which the piperlongumine works in animal models against glioblastoma.
An aggressive type of brain cancer, glioblastoma has no cure. Patients survive an average of 15 months after diagnosis, with fewer than 10% of patients surviving longer than five years. While researchers are investigating potential new therapies via ongoing clinical trials, a new study from Washington University in St. Louis suggests that a minor adjustment to the current standard treatment — giving chemotherapy in the morning rather than the evening — could add a few months to patients’ survival.
The public can vote in STAT Madness, which is like the scientific version of the NCAA basketball tournament.
Scientists say they have discovered a potential new target for immunotherapy of malignant brain tumors, which so far have resisted the ground-breaking cancer treatment based on harnessing the body’s immune system. The discovery, reported in the journal CELL, emerged from laboratory experiments and has no immediate implications for treating patients.
Stand Up to Cancer Canada Dream Team is combining strengths of Princess Margaret, SickKids, University of Toronto researchers, and other unique partnerships, to accelerate new cures for hard-to-treat cancers, such as glioblastoma.
The largest and most detailed molecular analysis yet of an aggressive brain cancer, called glioblastoma, reveals fundamental details that drive its growth. The
A new study led by Washington University School of Medicine in St. Louis has revealed a detailed map of the genes, proteins, infiltrating cells and signaling pathways that play key roles in driving glioblastoma. The study, of 99 tumors from patients, is the largest and most detailed schematic of this deadly brain tumor.
In a study of mice, researchers at the UCLA Jonsson Comprehensive Cancer Center have identified a new approach that combines an anti-psychotic drug, a statin used to lower high cholesterol levels, and radiation to improve the overall survival in mice with glioblastoma.
Henry Ford Cancer Institute is the first site in the world to activate two new treatments for glioblastoma (GBM), the deadliest form of brain cancer, as part of a patient-centered adaptive platform trial known as GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment).
Researchers at McGill University have identified a new cellular pathway that limits the growth and spread of brain tumors by controlling the recycling of cell surface receptor proteins. The study, which will be published January 14 in the Journal of Cell Biology (JCB), suggests that the pathway, which involves a protein called Rab35, is defective in many patients with glioblastoma and that restoring Rab35’s activity could be a new therapeutic strategy for this deadly form of brain cancer.
Anyone who sees Colin Clark, 57, running, cycling or swimming around the Big Island of Hawaii, likely notices his athleticism and the smile permanently adorning his face.
Combining chimeric antigen receptor (CAR) T cell therapy with a PAK4 inhibitor allowed the engineered cells to punch their way through and attack solid tumors, leading to significantly enhanced survival in mice.
Announcement of University Hospitals Cleveland Medical Center and UH Seidman Cancer Center obtaining the Medtronic Stealth Autoguide cranial robotic guidance platform for neurosurgery.
Researchers in China have discovered how brain cancer cells increase production of a key protein that allows them to evade the body’s immune system. The study, which will be published August 27 in the Journal of Experimental Medicine (JEM), suggests that targeting this cellular pathway could help treat the deadly brain cancer glioblastoma, as well as other cancers that are resistant to current forms of immunotherapy.
Anti-androgen therapy showed positive results in cell lines and animal models against glioblastoma, an aggressive form of brain cancer.
Laboratory research paves the way for a clinical trial to see if an FDA-approved drug used to prevent organ transplant rejection can work against glioblastoma, a type of aggressive brain tumor.
A Ludwig Cancer Research study has dissected how radiotherapy alters the behavior of immune cells known as macrophages found in glioblastoma (GBM) tumors and shown how these cells might be reprogrammed with an existing drug to suppress the invariable recurrence of the aggressive brain cancer.
The discovery of the oncogene responsible for glioblastoma could be the brain tumor’s Achilles’ heel, one researcher says.
An innovative use of focused ultrasound is showing promise against glioblastoma, the deadliest brain tumor, and could prove useful against other difficult-to-treat cancers.
In this study, researchers investigated if specific targeting of CD133+ glioblastoma with cutting-edge immunotherapy drugs could eradicate the most aggressive subpopulation of cells in the tumour. They also looked at the safety of CD133-targeting therapies on normal, non-cancerous human stem cells including hematopoietic stem cells which create blood cells and progenitor cells which can form one or more kinds of cells.
The deadly brain cancer glioblastoma (GBM) is often resistant to chemotherapy and radiation, but new research shows targeting stromal cells – the cells that serve as the connective tissue of the organs – may be an effective way of overcoming that resistance
University of California San Diego School of Medicine researchers created a new type of brain cancer model for glioblastoma using stem cells, CRISPR and gene sequencing.
Sara Piccirillo, PhD, is passionate about finding a way to beat glioblastoma, the most aggressive type of brain cancer. Her research focuses on a feature of glioblastoma tumors that appears to be the source of their strength: the extreme differences among their tumor cells.
However, San Diego Supercomputer Center (SDSC) Research Scientist Igor Tsigelny recently collaborated Researchers from the San Diego Supercomputer at UC San Diego and colleagues from Sweden’s Karolinska Institute and the Pasteur Institute in France released a study focused on improving the prognosis for glioblastoma patients.
Two different UC San Diego research teams identified the same molecule — αvβ5 integrin — as Zika virus’ key to brain cell entry. They found ways to take advantage of the integrin to both block Zika virus from infecting cells and turn it into something good: a way to shrink brain cancer stem cells.
For adult patients with brainstem high-grade gliomas — one of the rarest and deadliest forms of brain cancer — surgically removing the entire tumor may add many months or potentially years of survival beyond that offered by radiation and chemotherapy, according to results of a medical records study led by researchers at the Johns Hopkins Kimmel Cancer Center.
Glioblastomas are the most aggressive form of brain cancer – they grow and spread rapidly through the brain and are virtually impossible to eradicate, typically leading to death within one or two years of diagnosis. Scientists are constantly seeking more powerful targeted therapies, but so far without success — in part because glioblastomas are challenging to study in a laboratory setting.
Researchers at The University of Texas MD Anderson Cancer Center have identified a tenacious subset of immune macrophages that thwart treatment of glioblastoma with anti-PD-1 checkpoint blockade, elevating a new potential target for treating the almost uniformly lethal brain tumor.
What do you do when your best friend is diagnosed with a cancer that kills most of its patients within a few months? A few brave dog owners turned to Johns Hopkins, where veterinarians, radiologists and physicists have teamed up to conduct an experimental trial of a therapy they hope will extend the lives of their beloved pets.
A blood test that measures the amount of cell-free DNA (cfDNA) in the bloodstream – called a liquid biopsy – correlates with how patients will progress after they are diagnosed with glioblastoma (GBM), the deadliest and most common primary brain tumor in adults
Tulane University senior James Rogers has been charting a course in the name of research since he arrived on campus in the fall of 2016. Rogers’ journey has led him from New Orleans to Bethesda, Md., across the Atlantic to Scotland and, most recently, Switzerland, where he spent the summer as a visiting research scholar in the Brain Tumor Center at the University Hospital Zürich (USZ).
A new study published this week gives insight into how cancer immunotherapies might one day be delivered directly to the brain in order to treat brain tumors.
The multiple sclerosis drug teriflunomide, paired with targeted cancer therapy, markedly shrinks patient-derived glioblastomas grown in mice by reaching stem cells at the tumor’s root, according to a new UC San Diego School of Medicine study published in Science Translational Medicine.